Calcelar 25 Drug Interactions

Concurrent use of clozapine and CYP1A2, CYP2D6 or CYP3A4 inhibitors may result in increased clozapine exposure and increased risk of adverse effects.
Concurrent use of nebivolol, donepezil, brexpiprazole, doxorubicin, amitriptyline, tamsulosin, oxycodone, propranolol and CYP2D6 inhibitors may result in increased exposure to those medicines.
Concurrent use of eliglustat, fluoxetine and selected strong or moderate CYP2D6 inhibitors may result in increased those medicines exposure and subsequent prolongation of the QT interval.
Concurrent use of cinacalcet and desipramine, flecainide, doxepin, clomipramine, imipramine, vinblastine, protriptyline, amoxapine, nortriptyline, thioridazine, carvedilol, or trimipramine may result in increased those medicine exposure and plasma concentrations.
Concurrent use of ketoconazole and cinacalcet may result in increased bioavailability of cinacalcet and risk of hypocalcemia.
Concurrent use of indinavir, erythromycin, ritonavir, clarithromycin, nelfinavir, nefazodone, atazanavir, telithromycin, voriconazole, saquinavir, fosamprenavir, or delavirdine and cinacalcet may result in increased cinacalcet exposure and plasma concentrations.
Concurrent use of tamoxifen and cinacalcet may result in increased plasma levels of tamoxifen and decreased plasma levels of the active metabolite.